GlassScriptPhysician profile
Thomas C Bohmfalk
NPI 1083794077
$4,077.61
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,137 · 2020: $1,179 · 2021: $761.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $900.09 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $517.88 | 2019-2021 | |
| Lilly USA, LLC | $349.18 | 2019-2021 | |
| Astellas Pharma US INC | $305.26 | 2019-2021 | |
| Amarin Pharma, INC. | $271.65 | 2019-2021 | |
| Allergan, INC. | $251.46 | 2019-2020 | |
| Glaxosmithkline, LLC. | $219.61 | 2019-2021 | |
| Esperion Therapeutics, INC. | $167.44 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $152.01 | 2019-2021 | |
| Abbott Laboratories | $117.87 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.25 | 2019-2021 | |
| Amgen INC. | $77.76 | 2019-2021 | |
| Abbvie INC. | $76.45 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.55 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $60.20 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $46.66 | 2019-2021 | |
| Pfizer INC. | $44.76 | 2019 | |
| Shire North American Group INC | $41.43 | 2019 | |
| Arbor Pharmaceuticals, INC. | $41.06 | 2019-2021 | |
| Genentech USA, INC. | $35.28 | 2019-2021 | |
| Metuchen Pharmaceuticals | $29.96 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $26.90 | 2020 | |
| Mylan Specialty L.P. | $25.94 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $19.22 | 2021 | |
| Zyla Life Sciences, INC. | $17.29 | 2020 | |
| Ironshore Pharmaceuticals INC. | $16.70 | 2019 | |
| Sanofi Pasteur INC. | $14.32 | 2019 | |
| Aytu Biopharma, INC. | $12.31 | 2019 | |
| Avion Pharmaceuticals | $11.90 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.86 | 2019 | |
| Gilead Sciences, INC. | $11.58 | 2019 | |
| Eisai INC. | $11.40 | 2020 | |
| Supernus Pharmaceuticals, INC. | $11.38 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Bohmfalk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.